Search company, investor...

Verax Biomedical

veraxbiomedical.com

Founded Year

1999

Stage

Loan | Alive

Total Raised

$72.43M

Last Raised

$680K | 3 yrs ago

About Verax Biomedical

Verax Biomedical is the producer of the Platelet PGD Test, a test for bacterial contamination in platelets granted a Safety Measure claim by the FDA. The test can be used to extend the dating of apheresis platelets in plasma, the most common platelet type transfused in the U.S., from 5 to 7 days. This dating extension offers the opportunity for significant cost savings to the blood banking community while preserving a critical life giving resource.

Headquarters Location

148 Bartlett Street

Marlborough, Massachusetts, 01752,

United States

+1 508 755 7029

Missing: Verax Biomedical's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Verax Biomedical's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Verax Biomedical

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Verax Biomedical is included in 2 Expert Collections, including Medical Devices.

M

Medical Devices

8,614 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

H

Health IT

7,901 items

Verax Biomedical Patents

Verax Biomedical has filed 4 patents.

The 3 most popular patent topics include:

  • Immune system
  • Immunologic tests
  • Immunology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

7/27/2018

4/5/2022

Molecular biology, Monoclonal antibodies, Olfactory receptors, Biotechnology, Immunologic tests

Grant

Application Date

7/27/2018

Grant Date

4/5/2022

Title

Related Topics

Molecular biology, Monoclonal antibodies, Olfactory receptors, Biotechnology, Immunologic tests

Status

Grant

Latest Verax Biomedical News

As Red Cross moves to pricey blood treatment method, hospitals call for more choice

May 17, 2022

Americans generally don't spend much time thinking about the nation's blood supply. That's mainly because the collection and distribution system is safe and efficient. But there's a new behind-the-scenes challenge, according to some hospital officials, who fear a change in how blood platelets are handled will sharply increase the cost — and, in some cases, the number of transfusions needed — to treat cancer patients, trauma victims, and those undergoing surgery. The concern revolves around the American Red Cross, the nation's single-largest provider of blood products, which will exclusively use an expensive technology to reduce the risk of dangerous bacteria tainting platelets. But the move limits hospitals' choice of less expensive testing options, which are also effective. "We are very concerned the blood collection centers have decided what is best for our patients when we are on the front line," said Dr. Aaron Tobian , director of the transfusion medicine division at Johns Hopkins Hospital. His concerns are echoed by some in Congress, including Rep. Earl "Buddy" Carter (R-Ga.), who in February joined 12 other congressional Republicans in signing a letter to the Department of Health and Human Services asking whether something could be done to boost hospital choices for complying with blood safety guidelines. "This has impacted rural hospitals in particular," which have tight budgets, he told KHN. The switch by the Red Cross, which it expects to be fully implemented by next year, stems from a recommendation by the FDA in late 2020 to use any of three methods to reduce the risk of bacterial contamination in the blood platelets. Under those recommendations, hospitals can buy platelets specially processed to reduce pathogens, which is the method the Red Cross and some other, smaller suppliers are moving toward. Or blood centers can test samples of each unit of platelets, looking for bacterial contamination, at least 36 hours after the blood is collected. The other option is to use a rapid test for bacteria shortly before the platelets are transfused, which occurs in addition to a primary screening for bacteria after collection. The FDA did not rank the options. And many hospitals and blood centers already employ one or more of them. No test or process is 100% effective. "Each of those methods has pluses and minuses," said Dr. Claudia Cohn, chief medical officer for the nonprofit Association for the Advancement of Blood and Biotherapies, which represents health care providers involved with transfusion medicine. She is also a professor of laboratory medicine and pathology at the University of Minnesota. The FDA offered the guidance because platelet transfusions are associated with a higher risk of sepsis and fatality than any other blood component, with some research estimating the chance of a serious infection at 1 in 10,000. Platelet transfusions are important to prevent or treat bleeding in some patients, such as those who have certain types of cancer, are trauma accident victims, or are undergoing surgical procedures that can result in a large loss of blood. The Red Cross, which collects about 1 million units of platelets annually, chose the processing method that reduces pathogens, the most expensive option, adding about $150 more per unit to hospitals' costs for platelets. It precludes the use of the lowest-cost alternative, a $25 rapid test made by Verax Biomedical, because that test is not approved by the FDA for use on those processed platelets. The other testing method adds about $83 per unit. The Red Cross, which collects and distributes about 40% of the nation's overall blood supply, signed a five-year deal in April with California-based Cerus Corp., which provides the synthetic compound and ultraviolet illuminator used to process the platelets. Approved in 2014, it remains the only such system sold in the U.S. Platelets are already one of the most expensive blood products with an average per-unit price of $500. Pathogen reduction could translate into six-digit additional costs to small hospitals' annual expenses, and "$1.5 million to $3 million" to what large academic medical centers spend each year on platelets, said Tobian, based on a research paper he co-authored. Some of that might be passed along to patients — if they pay a percentage of their treatment costs, for instance, or in higher insurance premiums. But hospitals may also have to eat some of the additional expense. The financial effect on the Red Cross and other blood suppliers is unclear. Organizations that supply blood are seeing declining donations, and operate on thin margins, although platelets tend to be one of their most profitable products. Pathogen reduction allows the Red Cross to charge more for platelets, but it must also buy the processing system from Cerus. In its most recent IRS filings , covering the financial year that ended June 30, 2021, the Red Cross said its "biomedical services" brought in $1.89 billion in revenue, but cost $1.83 billion, a $49 million difference. Red Cross spokesperson Jenelle Eli said in an email that is "not a revenue number" but would not give more specifics. In some years, Red Cross' costs exceed revenue, she wrote, and in others, the opposite is true. Related Stories She also would not provide details on the cost of purchasing the system from Cerus, whose chief medical officer joined the company after holding a similar position at the Red Cross. Pathogen-reduced platelets, while requiring a higher upfront cost, are a better value for hospitals because they reduce bacterial risk "while also mitigating other pathogen threats, like parasites, viruses and even pathogens we may not know about yet," wrote Jessa Merrill , American Red Cross Biomedical Services communications director, in a separate email. It's a "ready-to-use product that doesn't require any testing or further manipulation." Hospitals say the other testing methods outlined by the FDA have advantages, also, including a longer shelf life for platelets. Platelets that are tested for bacteria can be used for up to seven days, as compared with the five-day life of the processed platelets. "We have to be very efficient," said Kazem Shirazi, a technical specialist in transfusion services at George Washington Hospital in Washington D.C., who spends part of his days juggling requests from surgeons for a supply in the operating rooms with the need to have a supply on hand in the emergency room. The reduced time frame for the platelets his hospital buys from the Red Cross means "we end up wasting more," Shirazi said. Patients probably won't know what method is used on the platelets they receive, although research indicates the more expensive option can sometimes increase the amount of product needed. The process is useful to kill pathogens, but also "makes for a platelet that doesn't do its job as well," said Cohn. A meta-analysis of 12 studies of cancer patients who received pathogen-reduced platelets found no increased risk of death or bleeding. However, it did show an increase in the "number of transfusions required." And that's an issue. Tobian at Johns Hopkins said physicians like to keep the number of transfusions to a minimum: "The safest transfusion is the one that can be avoided." Safety was another concern raised by Rep. Carter during an April 27 House Energy and Commerce Committee hearing. He mentioned three cases of platelet-linked sepsis since 2019. Those platelets had been processed with the pathogen-reduction method, the FDA said in a December memorandum . But Red Cross spokesperson Merrill dismissed Carter's example, saying that those cases "were not due to a failure of the pathogen reduction/inactivation, but instead due to a post-manufacturing issue." Some platelet contamination cases — in both processed or tested platelets — might involve tiny leaks or other damage in storage containers, suggested a paper published last year in the journal Transfusion. Two Cerus employees were among the authors. The view of the processing method may depend on the size of the hospital. Smaller hospitals, which don't have trauma centers or large cancer programs, use far fewer platelets each year than large academic centers, which might need 10,000 or more units annually. "Smaller centers love the pathogen-reduced platelets because they don't have to mess with it and it's easy and safe to use," said Cohn. But academic hospitals, which do a lot of transfusions, "are really frustrated," she said. "If their blood suppliers are only willing to offer one kind, they are constrained." This article was reprinted from khn.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Verax Biomedical Frequently Asked Questions (FAQ)

  • When was Verax Biomedical founded?

    Verax Biomedical was founded in 1999.

  • Where is Verax Biomedical's headquarters?

    Verax Biomedical's headquarters is located at 148 Bartlett Street, Marlborough.

  • What is Verax Biomedical's latest funding round?

    Verax Biomedical's latest funding round is Loan.

  • How much did Verax Biomedical raise?

    Verax Biomedical raised a total of $72.43M.

  • Who are the investors of Verax Biomedical?

    Investors of Verax Biomedical include Paycheck Protection Program, BioVentures Investors, CNF Investments, KB Partners, SightLine Partners and 7 more.

  • Who are Verax Biomedical's competitors?

    Competitors of Verax Biomedical include Velico Medical, Mercator MedSystems, Amsino International, Abaxis, Hansen Medical and 10 more.

Compare Verax Biomedical to Competitors

V
Velico Medical

Velico Medical, fka ZymeQuest, is engaged in the discovery, development and commercialization of enzymatic blood conversion processing systems for use in blood transfusion medicine. Enzymatic blood conversion aims to enable the precise and permanent conversion of groups A, B and AB red blood cells to ECO (Enzyme Converted O) red blood cells.

P
Pulse Metric

Pulse Metric designs, manufactures and markets products and services that transform a simple blood pressure reading into a powerful functional profile of the patients cardiovascular system, including cardiac output, vessel compliance, vascular resistance and left ventricular contractility. Within a minute of uploading a DynaPulse blood pressure waveform to the DynaPulse Analysis Center website, 17 hemodynamic parameters are calculated, displayed and trended, providing clinicians with numeric values profiling the hearts pumping performance, blood vessel elasticity and vascular resistance, against normative ranges.The company believes the simplicity of its methodology and the significance of the information provided to the physician will improve quality of care while reducing costs. Pulse Metric has been granted nine patents in support of its proprietary technology.

C
Cardiophotonics

Cardiophotonics develops non invasive blood monitors used to detect cardiac arrhythmia and dehydration

L
LifePoint

Lifepoint is a medical technology company developing rapid and cost effective, non-invasive, on-site diagnostic products. The Company has developed and will continue to develop patented, proprietary technologies utilizing saliva as a test specimen to provide blood equivalent diagnostic results without the need for blood or urine.

I
Investigen

Founded in 1998, Investigen, Inc., is an innovator in DNA testing, developing new processes to shorten testing time and reduce the cost of DNA diagnostic testing and detection of microorganisms and genetically modified organisms (GMOs). Investigen's tests have already demonstrated significant value for food quality assurance, health care, environmental safety, and industry.http://www.investigen.comDidier Perez, Phone: 510-964-9700, Email: didier@investigen.com

C
CardioOptics

CardioOptics is a developer of Trans-Blood Vision products to provide catheter-based direct visualization through blood using infrared light.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.